Shattuck reported Q4 2025 net loss of USD 12.6 million and a net loss per share of USD 0.12, with R&D expenses of USD 9.1 million and G&A expenses of USD 4.3 million. For FY 2025, Shattuck posted a net loss of USD 48.8 million and a net loss per share of USD 0.70, on total revenue of USD 1.0 million, with R&D expenses of USD 35.3 million and G&A expenses of USD 17.2 million. Cash, cash equivalents and short-term investments were USD 78.1 million as of Dec. 31, 2025, and the company reported approximately USD 94.5 million as of Feb. 28, 2026 (unaudited), following USD 21.4 million of gross proceeds from at-the-market share sales in Q1 2026. On the business side, Shattuck said its Phase 1 trial of DR3 blocking antibody SL-325 in healthy volunteers is ongoing and nearly complete, with data expected in Q2 2026; enrollment is complete across all six single-ascending dose cohorts, and full enrollment in the final multiple-ascending dose cohort is expected in Q2 2026. Subject to positive Phase 1 data and regulatory alignment, Shattuck expects to initiate a Phase 2 SL-325 trial in Crohn’s disease in Q3 2026. The company also said its lead DR3-based bispecific antibody has entered IND-enabling activities, with target disclosure and supporting preclinical data planned in H1 2026, and noted the November 2025 appointment of Michael Choi, M.D., as vice president of clinical development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050615PRIMZONEFULLFEED9666127) on March 05, 2026, and is solely responsible for the information contained therein.
Comments